Dompé, a family-owned global biopharmaceutical company with roots that date back over 150 years, built its legacy by following two principles: take calculated risks, and focus on need rather than precedent.Georgea Pasedis, PharmD, RPh, Dompé’s Senior Vice President and Global Head of Medical Affairs, moved into her current role by following similar principles. After earning her PharmD and practicing at the renowned Mass Eye and Ear in Boston, Dr. Psedis determined she could make a broader impact by transitioning to industry.In her medical affairs role, Dr. Pasedis discusses the science behind Dompé’s products with physicians worldwide. That education includes intel on rhNGF (recombinant human Nerve Growth Factor), the protein that forms the basis for Oxervate (cenegermin-bkbj) the first FDA-approved treatment for neurotrophic keratitis (NK).With podcast host Paul Karpecki, OD, FAAO, Dr. Pasedis discusses the mechanism of action behind Oxervate and how it helps both early- and late-stage NK patients.She also discusses how Dompé has remained a successful family-owned business for multiple generations. Its U.S. subsidiary, launched in 2018 in record time, serves as an example of Dompé’s approach to science, to education, and to improving eye health for patients worldwide.Listen to the podcast today to discover:How Dr. Pasedis’ nonlinear career path led her to Dompé.How Dompé harnesses innovation differently as a family-owned business.How Dompe built out its U.S. launch in only three months.Why physician education is so important when it comes to diagnosing and treating NK.Dompe’s long-term plan for Oxervate, including in both early- and late-stage NK patients.Advice for other professionals considering a transition from the clinic to industry.[Press Play]